Trials explore immune checkpoint blockade in NMIBC March 14, 2016 By William Parker MD Peter C. Black, MD, discusses the current state of immune checkpoint inhibition for bladder cancer in this article from Urology Times SUO internship program member William Parker, MD. AstraZeneca drug a breakthrough therapy for bladder cancer February 22, 2016 By Erin Bastick FDA has granted breakthrough therapy designation for durvalumab (MEDI4736, AstraZeneca) for the treatment of urothelial bladder cancer. Bladder cancer tests: What factors impact results? February 16, 2016 By Katie Murray DO Urology Times SUO internship program member Katie Murray, DO, reports on a study evaluating the differences in urine cytology and UroVysion FISH testing results among clinically meaningful patient subgroups. Study weighs impact of BCG shortage on outcomes February 16, 2016 By William Parker MD Urology Times SUO internship program member William Parker, MD, discusses a retrospective review of more than 100 patients at Columbia University Medical Center in New York. Uro Pipeline: 1st patients treated in phase III study of investigational BPH Tx January 01, 2016 By Benjamin P. Saylor Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment. Uro Pipeline: Phase III data show drug’s benefit in castrate-resistant PCa December 01, 2015 By Benjamin P. Saylor Other pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder. Uro Pipeline: IDE approval granted for implantable neurostimulator November 01, 2015 By Benjamin P. Saylor A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up. Work-related bladder cancer risk on the rise October 12, 2015 By Lisette Hilton Work-related risks for bladder cancer are on the rise, but the occupations putting workers at risk seem to be evolving, according to a meta-analysis published online in JAMA Oncology (Oct. 8, 2015). The promise of PD-1 ligand pathway in treating bladder cancer Researchers have recently made progress in understanding a fundamental signaling cascade, the Programmed Death 1 (PD-1) receptor-ligand pathway,1 which holds long-awaited promise in bladder cancer intervention. Reprogramming cancer with a code September 08, 2015 By Lisette Hilton Researchers at Mayo Clinic’s Jacksonville, Fla., campus reported a discovery that could be the code for reprogramming cancer cells back to normal.